Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Work In Process (2021 - 2024)

Protagonist Therapeutics' Work In Process history spans 4 years, with the latest figure at $165.0 million for Q4 2024.

  • For Q4 2024, Work In Process rose 1550.0% year-over-year to $165.0 million; the TTM value through Dec 2024 reached $165.0 million, up 1550.0%, while the annual FY2024 figure was $165.0 million, 1550.0% up from the prior year.
  • Work In Process for Q4 2024 was $165.0 million at Protagonist Therapeutics, up from $43000.0 in the prior quarter.
  • Across five years, Work In Process topped out at $300.0 million in Q1 2024 and bottomed at $10000.0 in Q4 2022.
  • The 4-year median for Work In Process is $1.6 million (2021), against an average of $68.1 million.
  • The largest annual shift saw Work In Process tumbled 99.36% in 2022 before it skyrocketed 99900.0% in 2023.
  • A 4-year view of Work In Process shows it stood at $1.6 million in 2021, then crashed by 99.36% to $10000.0 in 2022, then surged by 99900.0% to $10.0 million in 2023, then skyrocketed by 1550.0% to $165.0 million in 2024.
  • Per Business Quant, the three most recent readings for PTGX's Work In Process are $165.0 million (Q4 2024), $43000.0 (Q2 2024), and $300.0 million (Q1 2024).